Abstract:8058 Background: Bone metastases are common in patients with breast or prostate cancer and cause significant pain and skeletal morbidity. The need for radiation to bone to treat pain or prevent a fracture is a significant clinical event associated with disease progression and quality-of-life decline. Therefore, radiation to bone was included in the composite endpoints describing skeletal morbidity in recent clinical trials of zoledronic acid. Herein, a statistically robust nonparametric method was used to measure the cumulative burden of radiation to bone over the entire course of follow-up to evaluate the benefit of 4-mg zoledronic acid in patients with breast or prostate cancer enrolled in 2 large, randomized, phase III trials. We have previously reported by this method that zoledronic acid significantly reduces the overall cumulative incidence of skeletal complications compared with placebo or pamidronate (Pam) in these patient populations. Methods: These trials were GCP-compliant, and patients gave written informed consent. Patients received 4 mg zoledronic acid via 15-minute infusion every 3–4 weeks for 2 years. Comparators were 90 mg Pam via 2-hour infusion (breast cancer) or placebo (prostate cancer). Survival-adjusted multiple event analysis was performed via the methods of Cook et al. (Stat Med 1997;16;911–924) and Ghosh and Lin (Biometrics 2000;56:554–562). Results: In patients with breast cancer (n = 766), 4 mg zoledronic acid was superior to 90 mg Pam and significantly reduced the cumulative mean number of administrations of radiation to bone by 35.4% at 25 months (P = .003), adding to the benefit achieved with Pam. Similarly, in patients with prostate cancer, 4 mg zoledronic acid significantly reduced the cumulative mean number of administrations of radiation to bone by 33.2% compared with placebo at 24 months (P = .034). Conclusion: This new, robust method provides a simple graphic representation of the cumulative need for radiation therapy and reveals the significant reduction in need for radiation therapy achieved with zoledronic acid in breast or prostate cancer patients. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Novartis Pharmaceuticals Novartis (US)

Zoledronic acid in metastatic chondrosarcoma and advanced sacrum chordoma: two case reports

[Phase III Clinical Study of Zoledronic Acid in the Treatment of Pain Induced by Bone Metastasis from Solid Tumor or Multiple Myeloma].

Skeletal Complications in Patients with Bone Metastases from Renal Cell Carcinoma and Therapeutic Benefits of Zoledronic Acid

Long-term Efficacy and Safety of Zoledronic Acid in the Treatment of Skeletal Metastases in Patients with Nonsmall Cell Lung Carcinoma and Other Solid Tumors: a Randomized, Phase III, Double-Blind, Placebo-Controlled Trial.

Zoledronic Acid Versus Placebo in the Treatment of Skeletal Metastases in Patients with Lung Cancer and Other Solid Tumors: a Phase III, Double-Blind, Randomized Trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group.

Clinical Comparative Study of Zoledronic Acid Versus Pamidronate Disodium in the Treatment of Pain of Skeletal Metastases Lung Cancer

The role of zoledronic acid in cancer: clinical studies in the treatment and prevention of bone metastases

A multicenter randomized, double-blind and double dim comparative studies on zoledronic acid and pamidronate disodium: Phase II trials from 12 centers for treating bone metastasis pain

Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications.

Zoledronic Acid Reduces the Need for Radiation to Bone in Patients with Breast or Prostate Cancer Metastatic to Bone: A Survival-Adjusted Cumulative Incidence Analysis

Zoledronic Acid Combined with Chemotherapy Bring Survival Benefits to Patients with Bone Metastases from Nasopharyngeal Carcinoma

Bisphosphonate treatment in inaccessible osteoid osteomas: An alternative therapeutic approach

Survival-adjusted multiple-event analysis for the evaluation of treatment effects of zoledronic Acid in patients with bone metastases from solid tumors.

Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors

Phase II trial of zoledronic acid combined with androgen-deprivation therapy for treatment-naïve prostate cancer with bone metastasis

Zoledronic acid enhances tumor growth and metastatic spread in a mouse model of jaw osteosarcoma

Comparison of denosumab and zoledronic acid for the treatment of solid tumors and multiple myeloma with bone metastasis: a systematic review and meta-analysis based on randomized controlled trials

Randomized, Multicenter, Double - Blind, Double - Imitative, Comparative Trial of Zoledronic Acid Versus Pamidronate Disodium in the Treatment of Pain of Skeletal Metastases in Cancer Patients

The effect of zoledronic and pamidronate acid in treating bone pain in bone metastases of malignant tumor and its impact on serum calcium and phosphorus

Reactive Oxygen Species and Autophagy Associated Apoptosis and Limitation of Clonogenic Survival Induced by Zoledronic Acid in Salivary Adenoid Cystic Carcinoma Cell Line SACC-83

Strontium-89 plus zoledronic acid versus zoledronic acid for patients with painful bone metastatic breast cancer